SCHEMBL7161

SCHEMBL7161

CCOc1cccc(Br)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.61
MAPK8 P45983 1/20 0.49
BTK Q06187 1/20 0.45
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
ADORA1 P30542 2/20 0.40
ADORA2A P29274 1/20 0.40
GRM5 P41594 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
CDK9 P50750 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2525163 0.84 MAPK8 (0.56) HTR7MAPK8BTKGABRA1GABRG2
SCHEMBL6743 0.84 HTR7 (0.67) HTR7MAPK8GABRA1GABRG2GABRB3
SCHEMBL6377587 0.83 HTR7 (0.61) HTR7MAPK8BTKADORA1ADORA2A
SCHEMBL7285 0.82 HTR7 (0.65) HTR7GABRA1GABRG2GABRB3GABRA5
SCHEMBL12093509 0.81 GRM5 (0.50) HTR7MAPK8BTKADORA1ADORA2A
SCHEMBL29929586 0.80 HTR7 (0.57) HTR7MAPK8BTKGABRG2GABRB3
SCHEMBL19436605 0.80 HTR7 (0.57) HTR7MAPK8BTKGABRG2GABRB3
SCHEMBL7083 0.80 HTR7 (0.61) HTR7CDK9DYRK1ADYRK2
SCHEMBL8903035 0.80 HTR7 (0.61) HTR7CDK9DYRK1ADYRK2
SCHEMBL25097014 0.79 MAPK8 (0.49) HTR7MAPK8BTKALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
WO-2025076285-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 WO disclosed
CN-113490668-B Compounds and compositions for the treatment of diseases associated with APJ receptor activity 安娜普尔纳生物股份有限公司 2025-02-25 CN disclosed
EP-4364798-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY Annapurna Bio Inc. (US) 2024-05-08 EP disclosed
US-11944622-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2024-04-02 US disclosed
EP-3860998-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO INC (US) 2023-12-27 EP disclosed
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
US-11471455-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2022-10-18 US disclosed
US-4374251-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-02-15 US disclosed
US-4341787-A ANTIHISTAMINES; ANTISECRETORY AGENTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1982-07-27 US disclosed
US-4282221-A Pharmacologically active compounds to inhibit H-2 histamine receptors SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-08-04 US disclosed
US-4260744-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-04-07 US disclosed
US-4181730-A ANTISECRETORY AGENTS, IMIDAZOLYALKYLIMIDAZOLINONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-01-01 US disclosed
US-4153793-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-05-08 US disclosed
US-4152438-A HYPOTENSIVE AGENTS BEIERSDORF AKTIENGESELLSCHAFT (DE) 1979-05-01 US disclosed
US-4104381-A HISTAMINE INHIBITORS, ((IMIDAZOLYLALKYL)AMINO)THIADIAZINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-08-01 US disclosed
US-4005205-A PYRIMIDINE COMPOUNDS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-01-25 US disclosed
US-3941796-A α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 HTR7 1929/4885MAPK8 243/4885BTK 5/4885
US-11471455-B2 Compounds and compositions for treating conditions associated with APJ receptor activity APLNR, AGTR1, AGTR2 HTR7 2103/4885MAPK8 624/4885BTK 4782/4885
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 HTR7 2134/4885MAPK8 621/4885BTK 4781/4885
US-11944622-B2 Compounds and compositions for treating conditions associated with APJ receptor activity APLNR, AGTR1, AGTR2 HTR7 2134/4885MAPK8 621/4885BTK 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.